• MenB vaccine reduced IMD incidence by 78.3% in children aged 6 months to 5 years.
• Vaccine effectiveness was consistent across age subgroups and geographic regions.
• No significant increase in adverse events was observed in the MenB group.
• 95% of vaccinated children achieved protective antibody titers after the primary series.